<DOC>
	<DOCNO>NCT00041236</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness exatecan mesylate treat patient advanced soft tissue sarcoma .</brief_summary>
	<brief_title>Exatecan Mesylate Treating Patients With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine anticancer activity exatecan mesylate , term objective response duration response , patient advance soft tissue sarcoma . - Determine safety drug patient . OUTLINE : This multicenter study . Patients stratify accord histological diagnosis ( leiomyosarcoma v histology ) . Patients receive exatecan mesylate IV 30 minute daily day 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression . After disease progression , patient follow every 12 week survival . PROJECTED ACCRUAL : A total 32-50 patient ( 16-25 per stratum ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma include hemangiopericytoma Malignant peripheral nerve sheath tumor Unclassified sarcoma Miscellaneous sarcoma include mixed mesodermal tumor uterus The following tumor type exclude : Gastrointestinal stromal tumor Chondrosarcoma Malignant mesothelioma Neuroblastoma Osteosarcoma Ewing 's sarcoma Embryonal rhabdomyosarcoma Prior chemotherapy metastatic disease require One line combination chemotherapy contain anthracycline OR No 2 singleagent regimen include anthracycline Adjuvant chemotherapy consider first line unless tumor progress within 6 month treatment Must 1 measurable lesion Clinical evidence progression within 6 week prior study Osseous lesion pleural effusion consider measurable No know symptomatic CNS metastases PATIENT CHARACTERISTICS : Age : 15 75 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.8 mg/dL Albumin least 2.5 g/dL Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance great 65 mL/min Cardiovascular : No history severe cardiovascular disease Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No severe medical illness , include psychosis No prior concurrent malignancy except adequately treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics More 4 week since prior chemotherapy No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : No radiotherapy sole measurable lesion No concurrent radiotherapy Surgery : Not specify Other : No investigational drug 28 day prior , , 28 day completion study drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
</DOC>